120 related articles for article (PubMed ID: 8894076)
21. Personality dimensions in panic disorder before and after effective treatment.
Starcevic V; Uhlenhuth EH
Anxiety; 1996; 2(2):95-8. PubMed ID: 9160608
[No Abstract] [Full Text] [Related]
22. Alpha 2-adrenergic receptor sensitivity in panic disorder: II. Cortisol response to clonidine stimulation in panic disorder.
Brambilla F; Bellodi L; Arancio C; Nobile P; Perna G
Psychoneuroendocrinology; 1995; 20(1):11-9. PubMed ID: 7838899
[TBL] [Abstract][Full Text] [Related]
23. Moderators and mediators among panic, agoraphobia symptoms, and suicidal ideation in patients with panic disorder.
Huang MF; Yen CF; Lung FW
Compr Psychiatry; 2010; 51(3):243-9. PubMed ID: 20399333
[TBL] [Abstract][Full Text] [Related]
24. [Clinical picture and treatment of agoraphobia with panic disorder].
Litvintsev SV; Reznik AM; Kvashnina NV; Arbuzov AL; Krylov KE
Voen Med Zh; 2003 Jun; 324(6):53-9. PubMed ID: 12916423
[No Abstract] [Full Text] [Related]
25. The treatment of panic disorder in a clinical setting: a 12-month naturalistic study.
Marchesi C; Ampollini P; Signifredi R; Maggini C
Neuropsychobiology; 1997; 36(1):25-31. PubMed ID: 9211441
[TBL] [Abstract][Full Text] [Related]
26. Specific side effects of long-term imipramine management of panic disorder.
Mavissakalian M; Perel J; Guo S
J Clin Psychopharmacol; 2002 Apr; 22(2):155-61. PubMed ID: 11910260
[TBL] [Abstract][Full Text] [Related]
27. The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients.
van Megen HJ; Westenberg HG; den Boer JA; Slaap B; van Es-Radhakishun F; Pande AC
Psychopharmacology (Berl); 1997 Feb; 129(3):243-8. PubMed ID: 9084062
[TBL] [Abstract][Full Text] [Related]
28. Hypersensitivity to inhalation of carbon dioxide and panic attacks.
Perna G; Gabriele A; Caldirola D; Bellodi L
Psychiatry Res; 1995 Aug; 57(3):267-73. PubMed ID: 7501737
[TBL] [Abstract][Full Text] [Related]
29. Effect of fluvoxamine on panic disorder.
Hoehn-Saric R; McLeod DR; Hipsley PA
J Clin Psychopharmacol; 1993 Oct; 13(5):321-6. PubMed ID: 8227490
[TBL] [Abstract][Full Text] [Related]
30. Epinephrine infusions in panic disorder: a double-blind placebo-controlled study.
Veltman DJ; van Zijderveld GA; van Dyck R
J Affect Disord; 1996 Jul; 39(2):133-40. PubMed ID: 8827423
[TBL] [Abstract][Full Text] [Related]
31. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder.
Pande AC; Greiner M; Adams JB; Lydiard RB; Pierce MW
Biol Psychiatry; 1999 Sep; 46(6):860-2. PubMed ID: 10494457
[TBL] [Abstract][Full Text] [Related]
32. Treatment of panic disorder.
Cassano GB; Toni C; Musetti L
Adv Biochem Psychopharmacol; 1992; 47():449-60. PubMed ID: 1509926
[No Abstract] [Full Text] [Related]
33. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group.
Rosenbaum JF; Moroz G; Bowden CL
J Clin Psychopharmacol; 1997 Oct; 17(5):390-400. PubMed ID: 9315990
[TBL] [Abstract][Full Text] [Related]
34. Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics.
Sheehan DV; Raj AB; Harnett-Sheehan K; Dorotheo J; Sheehan MF; Trehan R; Knapp E; Swiontek A; Coleman B
Anxiety; 1996; 2(1):40-6. PubMed ID: 9160598
[No Abstract] [Full Text] [Related]
35. Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia.
Lesser IM; Lydiard RB; Antal E; Rubin RT; Ballenger JC; DuPont R
Am J Psychiatry; 1992 Nov; 149(11):1556-62. PubMed ID: 1415824
[TBL] [Abstract][Full Text] [Related]
36. Changes in appetite and weight during the pharmacological treatment of patients with panic disorder.
Balon R; Yeragani VK; Pohl R; Merlos B; Sherwood P
Can J Psychiatry; 1993 Feb; 38(1):19-22. PubMed ID: 8448714
[TBL] [Abstract][Full Text] [Related]
37. Response to sodium lactate in panic disorder: relationship to presenting clinical variables.
Cowley DS; Dunner DL
Psychiatry Res; 1988 Sep; 25(3):253-9. PubMed ID: 3186860
[TBL] [Abstract][Full Text] [Related]
38. Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report).
Slaap BR; van Vliet IM; Westenberg HG; den Boer JA
J Affect Disord; 1995 Jan; 33(1):31-8. PubMed ID: 7714306
[TBL] [Abstract][Full Text] [Related]
39. Influence of personality on behavioral response to cholecystokinin-tetrapeptide in patients with panic disorder.
Koszycki D; Zacharko RM; Bradwejn J
Psychiatry Res; 1996 May; 62(2):131-8. PubMed ID: 8771610
[TBL] [Abstract][Full Text] [Related]
40. Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder.
Brambilla F; Perna G; Garberi A; Nobile P; Bellodi L
Psychoneuroendocrinology; 1995; 20(1):1-9. PubMed ID: 7838898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
